- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00590538
Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)
A Pilot Trial of Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygous Cystic Fibrosis Patients
The purpose of this research study is to test a new combination of medicines, Phenylbutyrate and Genistein, to determine if they could be used to treat cystic fibrosis (CF). The most common genetic mutation found in patients with CF is called Delta F508. Due to this mutation, there is a lack of salt (chloride) movement in your nose, sinuses, lungs, intestines, pancreas and sweat glands. This lack of movement causes the clinical manifestations of the disease.
Although Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases, Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. When used together, both drugs may be able to restore normal chloride and salt (water) movements in body organs and glands in people with CF.
We will be studying salt and water movement in the nose by a technique called nasal transepithelial potential difference (NPD).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This protocol is investigating novel pharmaceutical agents (Phenylbutyrate and Genistein), which are aimed at improving the physiologic function of mutant Cystic Fibrosis Transmembrane conductance Regulator (CFTR). CFTR is absent or dysfunctional in cystic fibrosis. Nasal epithelial CFTR function will be assessed by the NPD procedure.
We will test the hypotheses that:
- Phenylbutyrate given orally for 4 days will be safe in adult Delta F508- heterozygous subjects with CF and will result in small improvements in nasal epithelial CFTR function.
- Topical administration of Genistein to the nasal epithelia of Phenylbutyrate treated Delta F508-heterozygous CF subjects will be safe and lead to augmentation of the improved nasal epithelial CFTR function observed during Phenylbutyrate treatment, but not during placebo treatment.
Study Flow If eligibility is confirmed at the screening visit, there will be an additional 3 outpatient visits over a 1-2 week period, lasting 2-4 hours each.
Visit 1, all study related safety evaluations will be completed. There will also be a Nasal Potential Difference (NPD) measurement performed. To measure nasal potentials, or voltages, a small butterfly needle will be placed in the skin of the forearm and connected by a thin plastic tube to a monitoring device. A very small soft plastic catheter or tube will be placed against the inner surface of the nose. This catheter will pump a very small amount of saltwater onto the nose and it will connect to the monitoring machine. This machine senses very small electrical voltages that are generated by the body. It does not and cannot send electricity or shocks to the subject. A measurement is made and then the fluid pumped into the nose is changed to one containing a drug called amiloride. Amiloride changes the makeup of salt transported in the nose and reduces the electrical voltage. Then the fluid is changed to saltwater that does not contain chloride. The fluid is then changed to one that has the drug isoproterenol. Isoproterenol causes the cells in subjects without CF to move chloride. The doses of amiloride and isoproterenol used in this study are much lower than those typically used in patients for other reasons. Finally, the fluid will be changed to one containing the experimental drug Genistein.
Subject will then be randomized and given a 4-day supply of the study drug.
Visit 2, subject will have safety evaluations and NPD performed in the same manner as previous visit. No more study drug after this visit.
Visit 3, subject will have safety evaluations and NPD performed without the perfusion of Genistein.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- The Children's Hospital of Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to communicate with pertinent staff, able to understand and willing to comply with the requirements of the trial, and able and willing to give informed consent.
- Willing to practice a reliable and study-accepted method of contraception during the study.
Diagnosis of cystic fibrosis consisting of both:
- clinical manifestations of cystic fibrosis and
- either cystic fibrosis genotype heterozygous for Delta F508 with a second identified CFTR mutation, or cystic fibrosis genotype with one Delta F508 allele and one unidentified allele and sweat sodium or chloride > 60 mEq/L
- Oxyhemoglobin saturation greater than or equal to 92% while breathing room air
Exclusion Criteria:
Underlying diseases likely to limit life span and/or increase risk of complications:
- Cancer requiring treatment in the past 5 years, with the exception of cancers that have been cured, or in the opinion of the investigator, carry a good prognosis such as non-melanoma skin cancer, papillary thyroid carcinoma, and cervical cancer in situ.
- GI disease
i. Inflammatory bowel disease requiring treatment in the past year ii. elevations in ALT or AST levels to greater than 3 times the upper limit of normal
Conditions or behaviors likely to affect the conduct of the study
- Current or anticipated participation in another intervention research project
- Recent (with 2 months) sinus surgery or nasal polypectomy
- Currently pregnant or less than 3 months post-partum
- Currently nursing or within 6 weeks of having completed nursing
- Unwilling to undergo pregnancy testing or to report possible or confirmed pregnancy promptly during the course of the study
- Unwilling to use a reliable contraceptive method for two months after the completion of the study.
- Major psychiatric disorder, which, in the opinion of the investigators, would impede conduct of the study, e.g., alcoholism
- Other condition, which, in the opinion of the investigators, would impede conduct of the study.
- Glucocorticoids other than topical, ophthalmic, and inhaled preparations.
Conditions that would place the patient at an increased risk for complications:
- Pneumothorax within the last 12 months
- Uncontrolled diabetes
- Asthma or allergic bronchopulmonary aspergillosis requiring systemic glucocorticoid therapy within the last two months
- Sputum culture growing a pathogen that does not have in vitro sensitivity to at least two types of antibiotics which could be administered to the patient
- History of major hemoptysis: (Greater than 240 mL of blood within a 24-hour period within the last 12 months).
- Medication use or conditions not specifically mentioned above, including severe or end stage CF lung disease, that may serve as criteria for exclusion at the discretion of the investigators.
- History of significant cardiovascular disease, such as myocardial infarction, congestive heart failure, unstable arrhythmia, or uncontrolled hypertension.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Phenylbutyrate
The standard oral adult dose is 20 g/day for 4 days. Every participant will receive Genistein during the NPD. |
The standard oral adult dose is 20 g/day (tablets) for 4 days.
Other Names:
Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure.
Other Names:
|
Placebo Comparator: Placebo
The placebo is given to match the active comparator for 4 days.
Every participant will receive Genistein.
|
Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure.
Other Names:
The placebo is given to match the active comparator for four days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Voltage (mVolt) in Nasal Epithelium
Time Frame: Baseline and 2 weeks
|
The basis of analysis for the primary outcome measure will be the comparison of data from both the standard CF Nasal Potential Difference (NPD) Protocol compared to a modified NPD protocol including the perfusion of Genistein. The NPD response will be compared from baseline to after study drug. NPD responses will then be compared between the Phenylbutrate group and the placebo group. |
Baseline and 2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in FEV1 (Forced Expiratory Volume in 1 Second) in Spirometry.
Time Frame: baseline and 2 weeks
|
Outcome measure will be obtained from standard Pulmonary Function testing.
|
baseline and 2 weeks
|
Change in FVC (Forced Vital Capacity)in Spirometry.
Time Frame: baseline and 2 weeks
|
Outcome measure will be obtained from standard Pulmonary Function testing.
|
baseline and 2 weeks
|
Number of Participants With Adverse Events
Time Frame: up to 2 weeks
|
Adverse Events will be assessed and outcome measure obtained by completion of Interval history, physical and mental status examinations of every participant.
|
up to 2 weeks
|
Number of Participants With Abnormal Laboratory Safety Tests
Time Frame: up to 2 weeks
|
Outcome measure will be obtained by completion of routine metabolic and hematological laboratory parameters for every participant.
Metabolic testing willl include a CMP (comprehensive metabolic panel, ALT (alanine aminotransferase test), GGT (gamma-glutamyl transpeptidase), and Uric Acid; Hematological testing will include a complete blood count (CBC), and partial thromboplastin (PT/PTT).
|
up to 2 weeks
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Pancreatic Diseases
- Fibrosis
- Cystic Fibrosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protective Agents
- Estrogens, Non-Steroidal
- Estrogens
- Protein Kinase Inhibitors
- Anticarcinogenic Agents
- Phytoestrogens
- Genistein
- 4-phenylbutyric acid
Other Study ID Numbers
- 2002-10-3023
- RUBENS01A0 (Other Identifier: Children's Hospital of Philadelphia)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on Sodium 4-Phenylbutyrate
-
WestatNational Institute of Neurological Disorders and Stroke (NINDS)TerminatedSpinal Muscular Atrophy Type IUnited States
-
Horizon Pharma Ireland, Ltd., Dublin IrelandCompletedUrea Cycle DisordersUnited States, Canada
-
WestatNational Institute of Neurological Disorders and Stroke (NINDS)TerminatedSpinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type IIIUnited States
-
Jerry Vockley, MD, PhDAcer Therapeutics Inc.RecruitingMedium-chain Acyl-CoA Dehydrogenase DeficiencyUnited States
-
US Department of Veterans AffairsMuscular Dystrophy AssociationCompletedAmyotrophic Lateral SclerosisUnited States
-
University of NottinghamRecruitingObese Non DiabeticUnited Kingdom
-
University of RochesterJohns Hopkins University; Massachusetts General Hospital; University of California... and other collaboratorsCompletedHuntington's DiseaseUnited States
-
International Centre for Diarrhoeal Disease Research...Karolinska Institutet; University of Iceland; National Institute of Diseases...CompletedPulmonary TuberculosisBangladesh
-
University of UtahEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedSpinal Muscular AtrophyUnited States
-
National Cancer Institute (NCI)CompletedLymphoma | Unspecified Adult Solid Tumor, Protocol SpecificUnited States